COVID-19 vaccines profits in 2022
It is known that the goal of vaccine developers is to mimic a natural infection as closely as possible without getting a healthy individual sick. The arrival of Covid-19 vaccines promises a return to more normal life and has created a global market worth tens of billions of dollars in annual sales for some pharmaceutical companies. Pfizer - One of the world’s largest pharmaceutical companies, based in New York, in collaboration with German biotech company BioNTech. - According to the first-quarter results published by Pfizer this week, its coronavirus jab BNT162b2, made in partnership with BioNTech, has reaped revenues of $3.5bn for the biopharma giant in the first three months of 2021. - Governments have ordered about 780m shots, including the US (200m doses for $3.9bn) and the EU commission (300m), while 40m doses will go to lower-income nations via the Covax facility. It costs $39 (£28) for two doses in the US and about $30 in the EU. - Expected sales in 2021: $15bn-$3